Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
68 hedge funds and large institutions have $195M invested in Albireo Pharma Inc in 2018 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 19 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
1% more funds holding
Funds holding: 67 → 68 (+1)
5% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 19
24% less capital invested
Capital invested by funds: $256M → $195M (-$61.4M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $49K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
+$5.21M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$2.83M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.48M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.07M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$883K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$3.96M |
| 2 |
Millennium Management
New York
|
-$2.18M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$1.13M |
| 4 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$1.08M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$484K |
ALBO Hedge Fund Activity: Q4 2018 in Review
68 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q4 2018, worth a combined $195M — down 24% from $256M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ALBO positions and 6 closed out — a net gain of 2 holders — while 20 added to existing stakes and 19 trimmed.
The largest buyer was Fosun International, opening a new position worth an estimated $5.21M. The largest seller was Deerfield Management, exiting entirely with an estimated $3.96M sold.
- 68 institutional investors held Albireo Pharma Inc (ALBO) as of Q4 2018, up from 67 in Q3 2018.
- Funds reported $195M of Albireo Pharma Inc stock for Q4 2018, down 24% quarter-over-quarter.
- 8 funds opened new Albireo Pharma Inc positions in Q4 2018 and 6 closed out, a net change of +2 holders.
- The largest Albireo Pharma Inc buyer in Q4 2018 was Fosun International, an estimated $5.21M added.
- The largest Albireo Pharma Inc seller in Q4 2018 was Deerfield Management, an estimated $3.96M sold.
Based on aggregated 13F filings for Q4 2018.